These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 27052278)

  • 1. Influence of the CYP4F2 polymorphism on the risk of hemorrhagic complications in coumarin-treated patients.
    Chen P; Sun YQ; Yang GP; Li R; Pan J; Zhou YS
    Saudi Med J; 2016 Apr; 37(4):361-8. PubMed ID: 27052278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Race-Specific Influence of CYP4F2 on Dose and Risk of Hemorrhage Among Warfarin Users.
    Shendre A; Brown TM; Liu N; Hill CE; Beasley TM; Nickerson DA; Limdi NA
    Pharmacotherapy; 2016 Mar; 36(3):263-72. PubMed ID: 26877068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of CYP4F2, ABCB1, and GGCX polymorphisms on bleeding episodes associated with acenocoumarol in Russian patients with atrial fibrillation.
    Sychev DA; Rozhkov AV; Kazakov RE; Ananichuk AV
    Drug Metab Pers Ther; 2016 Sep; 31(3):173-8. PubMed ID: 27662649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Body Mass Index and Genetics on Warfarin Major Bleeding Outcomes in a Community Setting.
    Hart R; Veenstra DL; Boudreau DM; Roth JA
    Am J Med; 2017 Feb; 130(2):222-228. PubMed ID: 27593608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of CYP4F2 polymorphism on response to warfarin during induction phase: a prospective, open-label, observational cohort study.
    Bejarano-Achache I; Levy L; Mlynarsky L; Bialer M; Muszkat M; Caraco Y
    Clin Ther; 2012 Apr; 34(4):811-23. PubMed ID: 22417713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals.
    Danese E; Raimondi S; Montagnana M; Tagetti A; Langaee T; Borgiani P; Ciccacci C; Carcas AJ; Borobia AM; Tong HY; Dávila-Fajardo C; Rodrigues Botton M; Bourgeois S; Deloukas P; Caldwell MD; Burmester JK; Berg RL; Cavallari LH; Drozda K; Huang M; Zhao LZ; Cen HJ; Gonzalez-Conejero R; Roldan V; Nakamura Y; Mushiroda T; Gong IY; Kim RB; Hirai K; Itoh K; Isaza C; Beltrán L; Jiménez-Varo E; Cañadas-Garre M; Giontella A; Kringen MK; Haug KBF; Gwak HS; Lee KE; Minuz P; Lee MTM; Lubitz SA; Scott S; Mazzaccara C; Sacchetti L; Genç E; Özer M; Pathare A; Krishnamoorthy R; Paldi A; Siguret V; Loriot MA; Kutala VK; Suarez-Kurtz G; Perini J; Denny JC; Ramirez AH; Mittal B; Rathore SS; Sagreiya H; Altman R; Shahin MHA; Khalifa SI; Limdi NA; Rivers C; Shendre A; Dillon C; Suriapranata IM; Zhou HH; Tan SL; Tatarunas V; Lesauskaite V; Zhang Y; Maitland-van der Zee AH; Verhoef TI; de Boer A; Taljaard M; Zambon CF; Pengo V; Zhang JE; Pirmohamed M; Johnson JA; Fava C
    Clin Pharmacol Ther; 2019 Jun; 105(6):1477-1491. PubMed ID: 30506689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant coumarin-NSAID therapy and risk for bleeding.
    Knijff-Dutmer EA; Schut GA; van de Laar MA
    Ann Pharmacother; 2003 Jan; 37(1):12-6. PubMed ID: 12503926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles.
    Oldenburg J; Bevans CG; Fregin A; Geisen C; Müller-Reible C; Watzka M
    Thromb Haemost; 2007 Sep; 98(3):570-8. PubMed ID: 17849045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol].
    Márk L; Márki-Zay J; Fodor L; Kondacs A; Paragh G; Katona A
    Orv Hetil; 2005 Apr; 146(16):739-43. PubMed ID: 15889670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for bleeding in patients taking coumarins.
    Beyth RJ; Milligan PE; Gage BF
    Curr Hematol Rep; 2002 Sep; 1(1):41-9. PubMed ID: 12901124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.
    Daly AK
    Arch Toxicol; 2013 Mar; 87(3):407-20. PubMed ID: 23376975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy.
    Eriksson N; Wallentin L; Berglund L; Axelsson T; Connolly S; Eikelboom J; Ezekowitz M; Oldgren J; Paré G; Reilly P; Siegbahn A; Syvanen AC; Wadelius C; Yusuf S; Wadelius M
    Pharmacogenomics; 2016 Aug; 17(13):1425-39. PubMed ID: 27488176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
    Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
    Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves.
    An SH; Lee KE; Chang BC; Gwak HS
    J Clin Pharm Ther; 2014 Jun; 39(3):314-8. PubMed ID: 24602049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implication of novel CYP2C9*57 (p.Asn204His) variant in coumarin hypersensitivity.
    Nahar R; Dube D; Parakh R; Deb R; Saxena R; Singh TP; Verma IC
    Thromb Res; 2013 Jun; 131(6):535-9. PubMed ID: 23582453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene polymorphisms and the risk of warfarin-induced bleeding complications at therapeutic international normalized ratio (INR).
    Pourgholi L; Goodarzynejad H; Mandegary A; Ziaee S; Talasaz AH; Jalali A; Boroumand M
    Toxicol Appl Pharmacol; 2016 Oct; 309():37-43. PubMed ID: 27581200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics role in the safety of acenocoumarol therapy.
    Jiménez-Varo E; Cañadas-Garre M; Henriques CI; Pinheiro AM; Gutiérrez-Pimentel MJ; Calleja-Hernández MÁ
    Thromb Haemost; 2014 Sep; 112(3):522-36. PubMed ID: 24919870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Ketoconazole, a CYP4F2 Inhibitor, and CYP4F2*3 Genetic Polymorphism on Pharmacokinetics of Vitamin K
    Park JW; Kim KA; Park JY
    J Clin Pharmacol; 2019 Nov; 59(11):1453-1461. PubMed ID: 31134657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic polymorphisms of patients on stable warfarin maintenance therapy in a Ghanaian population.
    Kudzi W; Ahorhorlu SY; Dzudzor B; Olayemi E; Nartey ET; Asmah RH
    BMC Res Notes; 2016 Dec; 9(1):507. PubMed ID: 27938396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of gene polymorphims on the warfarin treatment at initial stage.
    Liu J; Jiang HH; Wu DK; Zhou YX; Ye HM; Li X; Luo ZY; Guo Z; Zhang YL; Wang YC; Zhang W; Zhou HH; Wang LS
    Pharmacogenomics J; 2017 Jan; 17(1):47-52. PubMed ID: 26644206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.